Iron as a Therapeutic Target in Intracerebral Hemorrhage: Preclinical Testing of Deferoxamine

Intracerebral hemorrhage (ICH) is a subtype of stroke with high mortality. Experimental studies have found that brain iron overload occurs after ICH and iron has a key role in ICH-induced brain injuiry. Deferoxamine, an iron chelator, reduces hematoma-induced brain edema, neuronal death, brain atrophy and neurological deficits. Iron chelation with deferoxamine could be a new therapy for ICH.